Log in

Hikma Pharmaceuticals Stock Price, News & Analysis (LON:HIK)

GBX 1,993
-17.00 (-0.85 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
1,986.50
Now: GBX 1,993
2,026
50-Day Range
1,911
MA: GBX 2,047.57
2,200
52-Week Range
1,491.50
Now: GBX 1,993
2,212
Volume273,557 shs
Average Volume822,138 shs
Market Capitalization£4.83 billion
P/E Ratio13.39
Dividend Yield1.37%
BetaN/A
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-73992760

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.14 billion
Cash FlowGBX 139.89 per share
Book ValueGBX 756.30 per share

Profitability

Miscellaneous

Employees8,400
Market Cap£4.83 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Friday, August 9th. Investors of record on Thursday, August 22nd will be paid a dividend of GBX 0.14 per share on Monday, September 23rd. This represents a dividend yield of 0.59%. The ex-dividend date is Thursday, August 22nd. The official announcement can be seen at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

7 brokerages have issued 12-month price targets for Hikma Pharmaceuticals' stock. Their predictions range from GBX 1,350 to GBX 2,250. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 1,848.57 in the next year. This suggests that the stock has a possible downside of 7.2%. View Analyst Price Targets for Hikma Pharmaceuticals.

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Media stories about HIK stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,993.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £4.83 billion and generates £2.14 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.View Additional Information About Hikma Pharmaceuticals.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  673 (Thanks for Voting!)
Underperform Votes:  522 (Thanks for Voting!)
Total Votes:  1,195
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Quantitative Easing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel